Technology transfer: helping you translate your discovery into the next healthcare innovation!
How we can help
If you are an MRC-employed scientist, MRC Technology (MRCT) can help you to translate your work. We protect and commercialise novel ideas, and could provide funding to get them to the next stage of development.
In addition, MRCT’s Centre for Therapeutic Discovery (CTD) works with academic researchers from any institution on small molecules early stage drug discovery programmes and antibody humanisation projects. CTD has over 100 people years of pharmaceutical company experience in computational chemistry, medicinal chemistry, assay development and screening, and antibody humanization.
Who we work with
MRC Technology (MRCT) carries out technology transfer operations on behalf of the Medical Research Council to protect, develop and commercialise work carried out by its academic researchers.
How we work
MRCT has a well established process for translating academic research into commercial success. Our team of Business Managers has extensive experience in finding and assessing innovative ideas, and partnering them with our industry contacts.
Any revenue generated from commercialising academic research is shared with the originator and their institution to be re-invested in research.
To find out more simply get in touch.
News feed
Barbara Saxty has co-authored a Nature Communications paper entitled An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid.
The University of Leicester is recruiting for an MRCT-supported Research Fellow
MRCT are collaborating with the University of Bristol to develop orally available small molecule TrkA antagonists for treatment of chronic intractable pain.
MRC Technology’s Therapeutic Antibody Group and The University of Aberdeen work together on project to develop therapeutic against a novel cancer target, soluble CTLA-4.